TORONTO and HAIFA, Israel, Dec. 06, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (NRX:CA), (OTCQB: NRXBF), (Germany: J90) ("NurExone" or the "Company"), a ...

In experiments in mouse tissues and human cells, researchers say they have found that removing a membrane that lines the back of the eye may improve the success rate for regrowing nerve cells damaged ...

NurExone Biologic Inc. has reported promising preclinical results for its drug ExoPTEN, which shows potential in repairing optic nerve damage and restoring vision, particularly for conditions like ...

NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries, while also conducting preclinical tests for other conditions that ...

Researchers in Australia are claiming an important breakthrough in glaucoma research, demonstrating how the degenerative condition can be treated using an innovative form of gene therapy. The ...

NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries, while also conducting preclinical tests for other conditions that ...

The use of GLP-1 receptor agonists, and particularly liraglutide, was associated with an increased risk of developing nonarteritic anterior ischemic optic neuropathy (NAION) during the first year of ...

Each year thousands of patients face life-long losses in sensation and motor function from spinal cord injury and related conditions in which axons are badly damaged or severed. New research in mice ...

When the axons that extend from neurons break during a spinal cord injury, the result is often a lifelong loss of motor functioning, because vital connections from the brain to other body parts cannot ...

Increased intraocular pressure (lOP) is recognised as the principal risk factor for the development of glaucomatous cupping of the optic disc. The hypothesis that it disrupts the function of retinal ...